- Kiplinger•4 days ago
Thinkstock If you had invested $100,000 five years ago in a low-cost fund that tracks Standard & Poor's 500-stock index, you'd be sitting pretty today. Over that period, the index has returned an annualized ...
- PR Newswire•4 days agoPerrigo Invests In Tarex® Patented Technology, As A Key Investment In The Fight Against Methamphetamine Drug Abuse
TASE) today announced an exclusive licensing agreement with Highland Pharmaceuticals, LLC for its Tarex® methamphetamine ("meth") blocking technology and the distribution rights of Zephrex-D® (pseudoephedrine HCI 30 mg). Zephrex-D® was developed using the Tarex® technology and has been proven to be more than 98% effective at blocking one of the more common domestic methods of illegal meth production. This agreement is part of Perrigo's ongoing efforts in the fight against meth drug abuse. Perrigo's Executive Vice President & President, Consumer Healthcare - Americas, Jeff Needham commented that, "Across the country, illegal methamphetamine use continues to be a significant issue.
- Market Realist•10 days ago
Share price estimates for Valeant Valeant Pharmaceuticals (VRX) operates in the specialty pharmaceutical industry. With controversies associated with its huge debt, price gouging, and the Philidor controversy, ...
Perrigo Company plc (PRGO)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||91.12 x 100|
|Ask||92.64 x 100|
|Day's Range||91.64 - 94.23|
|52wk Range||82.50 - 167.92|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-147.96|
|Avg Vol (3m)||2,121,884|
|Dividend & Yield||0.58 (0.60%)|